FDA Can Regulate Stem Cell Treatments, DC Circ. Rules

Law360, Los Angeles (February 4, 2014, 5:00 PM EST) -- The D.C. Circuit on Tuesday ruled that Regenerative Sciences LLC's stem cell treatment is a drug and therefore subject to U.S. Food and Drug Administration regulations, rejecting the company's claims that its process is a medical procedure subject to state laws.

The appeals court affirmed a district court’s orders granting summary judgment and an injunction to the government just three months after Regenerative Sciences blasted the FDA’s attempt to regulate the Regenexx procedure, which uses a patient's stem cells mixed with an antibiotic to treat joint, muscle,...
To view the full article, register now.